In Generics, An Update on Reform
Executive Summary
The new Medicare Act, while aimed at expanding health insurance coverage to include drug benefits, also includes some changes that wiill impact the intricate and highly evolved way generic companies go about challenging patents on brand-name drugs. Specifically, it strengthens an incentive companies have to be first to file a patent challenge, known as 180-day marketing exclusivity. Second, it limits the number of times a brand name company can get a delay on launch of a newly approved generic.
You may also be interested in...
Authorized Generics: Band-Aid or Strategy?
In the past two years, some Big Pharma companies have revitalized their long-dormant generics activities and launched generic copies of their own drugs. They're doing this to capture business they would otherwise lose completely and to tie up generics competitors in court. While similar strategies failed in the past, a number of changes may make it more feasible. Innovators are behaving more rationally about pricing. And they are going after the most lucrative part of the generics business.
Pfizer v. Reddy: Drug Patents Under Fire
Generic firms are attacking drug patents--even before they expire--with increasingly clever legal strategies. And it looks like the FDA may be helping them do it.
Generic Update: Brand-Name Companies Vs. Independents
After a year of disappointments, many brand-name companies are retreating from generics businesses. Generic companies, for their part, still struggle with managed care.